Biological descriptionATP-competitive CDK inhibitor (IC50 values are 7 (CDC2/cyclin B), 7 (CDK2/cyclin A), 7 (CDK2/cyclin E), 3 (CDK/p35 kinase) and 25 μM (ERK1/p44 MAPK)). Inhibits cell cycle progression in vitro and in vivo.
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in DMSO to 50 mM and in ethanol to 25 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Zhu Z et al. Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia55:546-58 (2007).
Read more (PubMed: 17243097) »
Raynaud FI et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res11:4875-87 (2005).
Read more (PubMed: 16000586) »